NASDAQ:RCKTW Rocket Pharmaceuticals (RCKTW) Stock Price, News & Analysis $0.04 0.00 (-4.20%) As of 08/29/2025 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock About Rocket Pharmaceuticals Stock (NASDAQ:RCKTW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.1452-Week Range$0.02▼$0.15Volume27,531 shsAverage Volume24,471 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare and often fatal inherited diseases. The company utilizes ex vivo lentiviral vector-based approaches to deliver functional copies of genes into patients’ hematopoietic stem cells. By targeting the underlying genetic defects, Rocket aims to provide potentially curative treatments for disorders that currently rely on lifelong supportive care or conventional interventions. Rocket’s pipeline comprises multiple programs in various stages of development, including treatments for Fanconi anemia, primary immune deficiencies such as PNP deficiency and ADA-SCID, as well as metabolic and cardiac conditions like Danon disease and Barth syndrome. Several of these programs have advanced into clinical trials, reflecting the company’s emphasis on accelerating therapies from preclinical proof-of-concept through regulatory milestones. Founded in 2013 and headquartered in New York, Rocket Pharmaceuticals operates primarily in the United States while collaborating with academic and clinical partners across North America and Europe. The company is led by a management team with extensive experience in gene therapy, hematology and rare disease drug development, and it continues to expand its manufacturing and clinical infrastructure to support future growth.AI Generated. May Contain Errors. Read More Receive RCKTW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCKTW Stock News HeadlinesRocket Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 28, 2025 | finance.yahoo.comBank of America Upgrades Rocket Pharma Stock (RCKT) After FDA Lifts Clinical Hold on Danon Disease TrialAugust 21, 2025 | msn.com"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That's why we've rushed to update our book "Crypto Revolution" – to show you exactly how to position yourself for this historic opportunity.September 1 at 2:00 AM | Crypto 101 Media (Ad)B of A Securities Upgrades Rocket Pharmaceuticals (RCKT)August 21, 2025 | msn.comRocket Pharma rises as FDA lifts clinical hold on gene therapy trialAugust 20, 2025 | msn.comRocket Pharmaceuticals stock soars after FDA lifts clinical holdAugust 20, 2025 | investing.comRocket Pharmaceuticals upgraded to Buy from Neutral at BofAAugust 20, 2025 | msn.comRocket Pharma's shares soar after US FDA lets gene therapy trial resumeAugust 20, 2025 | msn.comSee More Headlines RCKTW Stock Analysis - Frequently Asked Questions How have RCKTW shares performed this year? Rocket Pharmaceuticals' stock was trading at $0.0343 at the beginning of the year. Since then, RCKTW stock has increased by 13.1% and is now trading at $0.0388. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RCKTW CIK1281895 Webwww.rocketpharma.com Phone16464409100FaxN/AEmployees240Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:RCKTW) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.